Marco Meglio on Muck Rack

Marco Meglio

Verified
Cranbury
As seen in: NeurologyLive, NeurologyLive® Mind Moments®, NewsBreak, HCP Live, Contagion Live, American Journal of Managed Care, Contemporary OB/GYN, Diagnostic Imaging, Managed Healthcare Executive, Patient Care, Neurology Times, MS Views and News (MSVN) and
Editor, @Neurology_Live 🧠| Hofstra Alum | Views are my own | 📧mmeglio@neurologylive.com | bagel and basketball enthusiast
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Marco

Contact Marco, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ASGCT 2026: GS-100 Gene Therapy Demonstrates Early Activity in NGLY1 Deficiency

|
By Thomas Crawford, Noah Stansfield, Marco Meglio Verified
| CGTLive
Interim findings from the ongoing first-in-human phase 1/2/3 trial of GS-100 (Grace Sciences), an investigational intracerebroventricular (ICV) AAV9 gene therapy for NGLY1 Deficiency, showed early improvements in motor and cognitive function among treated children, alongside a dose-dependent safety profile that informed dose selection for the pivotal portion of the study.¹ Presented at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting by Becky Schweighardt, PhD, and...
Open in Who Shared Issue with article?

Lonvo-z Advances Toward Approval as First In Vivo CRISPR Therapy for Hereditary Angioedema

|
By Jerel Banks, Noah Stansfield, Marco Meglio Verified
| CGTLive
Intellia Therapeutics has initiated a rolling biologics license application (BLA) submission to the FDA for lonvoguran ziclumeran (lonvo-z), an investigational one-time CRISPR-based gene editing therapy for hereditary angioedema (HAE), following phase 3 data showing substantial reductions in attack rates and treatment burden.¹ The application is supported by topline results from the global phase 3 HAELO trial, which met its primary and all key secondary endpoints, marking what could become...
Open in Who Shared Issue with article?

Regeneron’s Nets Accelerated Approval From FDA for Otoferlin-Related Hearing Loss Gene Therapy Lunsotogene Parvec

|
By Jerel Banks, Noah Stansfield, Marco Meglio Verified
| CGTLive
The FDA has granted accelerated approval to Otarmeni (lunsotogene parvec-cwha), an adeno-associated virus (AAV) vector–based gene therapy, for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss associated with biallelic pathogenic variants in the OTOF gene.1 Eligible patients must have preserved outer hair cell function and no prior cochlear implant in the affected ear.
Open in Who Shared Issue with article?
See all 89 licensed articles (5,046 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified